Health Economics
201 – 210 of 307
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.
2014) In Diabetes therapy : research, treatment and education of diabetes and related disorders 5(2). p.591-607(
- Contribution to journal › Article
-
Mark
Gender and Social Disparities in Esophagus Cancer Incidence in Iran, 2003-2009: A Time Trend Province-level Study.
(
- Contribution to journal › Article
-
Mark
Towards a Health Economic Simulation Model of Type 2 Diabetes in Sweden
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Predicting mortality in people with Type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data
(
- Contribution to journal › Article
-
Mark
Overall, gender and social inequalities in suicide mortality in Iran, 2006-2010: a time trend province-level study.
(
- Contribution to journal › Article
-
Mark
Willingness to pay for a new drug delivery in Parkinson patients.
(
- Contribution to journal › Article
-
Mark
Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations.
(
- Contribution to journal › Article
-
Mark
Decision-Analytic Models: Current Methodological Challenges
(
- Contribution to journal › Article
-
Mark
Health utilities of type 2 diabetes-related complications: a cross-sectional study in sweden.
(
- Contribution to journal › Article
-
Mark
On-demand treatment in persons with severe haemophilia
(
- Contribution to journal › Scientific review